TY - JOUR
T1 - Phase III study of the European Organisation for research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire
AU - Van leeuwen, Marieke
AU - Kieffer, Jacobien m.
AU - Young, Teresa
AU - Annunziata, Maria antonietta
AU - Arndt, Volker
AU - Arraras, Juan ignacio
AU - Autran, Didier
AU - Hani, Hira bani
AU - Chakrabarti, Manas
AU - Chinot, Olivier
AU - Cho, Juhee
AU - Da costa vieira, Rene aloisio
AU - Darlington, Anne-Sophie
AU - Debruyne, Philip r.
AU - Dirven, Linda
AU - Doege, Daniela
AU - Eller, Yannick
AU - Eichler, Martin
AU - Fridriksdottir, Nanna
AU - Gioulbasanis, Ioannis
AU - Hammerlid, Eva
AU - Van hemelrijck, Mieke
AU - Hermann, Silke
AU - Husson, Olga
AU - Jefford, Michael
AU - Johansen, Christoffer
AU - Kjaer, Trille kristina
AU - Kontogianni, Meropi
AU - Lagergren, Pernilla
AU - Lidington, Emma
AU - Lisy, Karolina
AU - Morag, Ofir
AU - Nordin, Andy
AU - Al omari, Amal s.h.
AU - Pace, Andrea
AU - De padova, Silvia
AU - Petranovia, Duska
AU - Pinto, Monica
AU - Ramage, John
AU - Rammant, Elke
AU - Reijneveld, Jaap
AU - Serpentini, Samantha
AU - Sodergren, Sam
AU - Vassiliou, Vassilios
AU - Leeuw, Irma verdonck-De
AU - Vistad, Ingvild
AU - Young, Teresa
AU - Aaronson, Neil k.
AU - van de Poll-Franse, L.V.
PY - 2023
Y1 - 2023
N2 - PurposeThe purpose of this study is to develop a European Organisation for Research and Treatment of Cancer Quality of Life Group (EORTC QLG) questionnaire that captures the full range of physical, mental, and social health-related quality of life (HRQOL) issues relevant to disease-free cancer survivors. In this phase III study, we pretested the provisional core questionnaire (QLQ-SURV111) and aimed to identify essential and optional scales.MethodsWe pretested the QLQ-SURV111 in 492 cancer survivors from 17 countries with one of 11 cancer diagnoses. We applied the EORTC QLG decision rules and employed factor analysis and item response theory (IRT) analysis to assess and, where necessary, modify the hypothesized questionnaire scales. We calculated correlations between the survivorship scales and the QLQ-C30 summary score and carried out a Delphi survey among healthcare professionals, patient representatives, and cancer researchers to distinguish between essential and optional scales.ResultsFifty-four percent of the sample was male, mean age was 60 years, and, on average, time since completion of treatment was 3.8 years. Eleven items were excluded, resulting in the QLQ-SURV100, with 12 functional and 9 symptom scales, a symptom checklist, 4 single items, and 10 conditional items. The essential survivorship scales consist of 73 items.ConclusionsThe QLQ-SURV100 has been developed to assess comprehensively the HRQOL of disease-free cancer survivors. It includes essential and optional scales and will be validated further in an international phase IV study.
AB - PurposeThe purpose of this study is to develop a European Organisation for Research and Treatment of Cancer Quality of Life Group (EORTC QLG) questionnaire that captures the full range of physical, mental, and social health-related quality of life (HRQOL) issues relevant to disease-free cancer survivors. In this phase III study, we pretested the provisional core questionnaire (QLQ-SURV111) and aimed to identify essential and optional scales.MethodsWe pretested the QLQ-SURV111 in 492 cancer survivors from 17 countries with one of 11 cancer diagnoses. We applied the EORTC QLG decision rules and employed factor analysis and item response theory (IRT) analysis to assess and, where necessary, modify the hypothesized questionnaire scales. We calculated correlations between the survivorship scales and the QLQ-C30 summary score and carried out a Delphi survey among healthcare professionals, patient representatives, and cancer researchers to distinguish between essential and optional scales.ResultsFifty-four percent of the sample was male, mean age was 60 years, and, on average, time since completion of treatment was 3.8 years. Eleven items were excluded, resulting in the QLQ-SURV100, with 12 functional and 9 symptom scales, a symptom checklist, 4 single items, and 10 conditional items. The essential survivorship scales consist of 73 items.ConclusionsThe QLQ-SURV100 has been developed to assess comprehensively the HRQOL of disease-free cancer survivors. It includes essential and optional scales and will be validated further in an international phase IV study.
U2 - 10.1007/s11764-021-01160-1
DO - 10.1007/s11764-021-01160-1
M3 - Article
SN - 1932-2259
VL - 17
SP - 1111
EP - 1130
JO - Journal of Cancer Survivorship
JF - Journal of Cancer Survivorship
ER -